Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mesoglycan (Prisma®) Versus Placebo in Secondary Prevention of the Superficial Venous Thrombosis

NCT03428711 is registered in ClinicalTrials.gov with Quovadis Associazione as lead sponsor.

NCT NCT03428711
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03428711 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mesoglycan (Prisma®) Versus Placebo in Secondary Prevention of the Superficial Venous Thrombosis
Lead sponsor
Quovadis Associazione
Phase
Phase 2
Overall status
Completed
Start date
March 26, 2018
Completion date
December 31, 2024
Enrollment
560 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

superficial venous thrombosis of leg, secondary prevention